Supplementary Table 1. Clinical characteristics of patients who had received platinum-based chemotherapy, n(%)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | CBDCA(n=142,314) | CDDP(n =86,316) | p |
|  |  |
| Age (years) | 20-59 | 19,355  | (13.6) | 22,793  | (26.4) | <0.001 |
|  | 60-69 | 52,909  | (37.2) | 43,422  | (50.3) |  |
|  | ≥70 | 70,050  | (49.2) | 20,101  | (23.3) |  |
| Sex  | Female | 35,335  | (24.8) | 20,842  | (24.1) | <0.001 |
| Body mass index (kg/m2)  | 18.5-22.9 | 66,490  | (46.7) | 41,884  | (48.5) | <0.001 |
|  | -18.4 | 20,108  | (14.1) | 10,245  | (11.9) |  |
|  | 23-25.9 | 36,610  | (25.7) | 23,148  | (26.8) |  |
|  | ≥26 | 17,219  | (12.1) | 10,182  | (11.8) |  |
|  | Missing | 1,887  | (1.3) | 857  | (1.0) |  |
| Smoking (pack-year) | 0 | 37,617  | (26.4) | 22,066  | (25.6) | <0.001 |
|  | 0.1-29.9 | 18,283  | (12.8) | 12,562  | (14.6) |  |
|  | ≥30 | 73,885  | (51.9) | 44,841  | (51.9) |  |
|  | Missing | 12,529  | (8.8) | 6,847  | (7.9) |  |
| Barthel Index | <100 | 16,279  | (11.4) | 4,424  | (5.1) | <0.001 |
|  | 100 | 123,381  | (86.7) | 80,447  | (93.2) |  |
|  | Missing | 2,654  | (1.9) | 1,445  | (1.7) |  |
| Radiotherapy |  | 15,121  | (10.6) | 10,954  | (12.7) | <0.001 |
| Central vein catheter |  | 3,641  | (2.6) | 2,590  | (3.0) | <0.001 |
| Thoracic drainage |  | 3,317  | (2.3) | 1,175  | (1.4) | <0.001 |
| Thoracentesis |  | 3,496  | (2.5) | 1,128  | (1.3) | <0.001 |
| Hypertension |  | 33,093  | (23.3) | 17,757  | (20.6) | <0.001 |
| Diabetes |  | 23,541 | (16.5) | 11,792  | (13.7) | <0.001 |
| Hyperlipidemia |  | 11,617  | (8.2) | 6,170  | (7.1) | <0.001 |
| Atrial fibrillation |  | 3,577  | (2.5) | 1,197  | (1.4) | <0.001 |
| Valvular disorder |  | 374  | (0.3) | 123  | (0.1) | <0.001 |
| Varix |  | 35  | (0.0) | 29  | (0.0) | 0.245  |
| Antithrombotic medication | 3,223  | (2.3) | 1,116  | (1.3) | <0.001 |

CBDCA, carboplatin; CDDP, cisplatin

Supplementary Table 2. Outcomes of patients who had received platinum-based chemotherapy

|  |  |  |  |
| --- | --- | --- | --- |
|  | CBDCA (n=142,314) | CDDP(n =86,316) | p |
|  |
| Venous thromboembolic events, n (%) | 371  | (0.26) | 298  | (0.35) | <0.001 |
|  Deep venous thrombosis | 227  | (0.16) | 204  | (0.24) | <0.001 |
|  Pulmonary embolism | 116  | (0.08) | 70  | (0.08) | 0.998 |
|  Others | 51  | (0.04) | 43  | (0.05) | 0.111 |
| Length of hospital stay, median (IQR) | 17 | (9-25) | 12 | (8-22) | <0.001 |
| Inhospital death, n (%) | 4,227  | (3.0) | 1,031  | (1.2) | <0.001 |

CBDCA, carboplatin; CDDP, cisplatin; IQR, interquartile range

Supplementary Table 3. Multivariable logistic regression analysis for venous thromboembolic events

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 　 | 　 | Adjusted odds ratio | 95% confidence interval | p |
| Platinum | CBDCA | Reference |  |  |  |  |
|  | CDDP | 1.50  | 1.16  | - | 1.94  | 0.002  |
| Age (years) | 20-59 | Reference |  |  |  |  |
|  | 60-69 | 0.88  | 0.68  | - | 1.14  | 0.333  |
|  | ≥70 | 0.75  | 0.56  | - | 1.00  | 0.049 |
| Sex | Female | 1.17  | 0.90  | - | 1.53  | 0.241  |
| Body mass index (kg/m2) | 18.5-22.9 | Reference |  |  |  |  |
|  | <18.5 | 1.03  | 0.73  | - | 1.43  | 0.883  |
|  | 23-25.9 | 0.97  | 0.74  | - | 1.27  | 0.805  |
|  | ≥26 | 1.21  | 0.87  | - | 1.68  | 0.250  |
|  | Missing | 0.86  | 0.35  | - | 2.08  | 0.733  |
| Smoking (pack-year) | 0 | Reference |  |  |  |  |
|  | 0.1-29.9 | 0.99  | 0.73  | - | 1.35  | 0.973  |
|  | ≥30 | 0.69  | 0.53  | - | 0.90  | 0.006  |
|  | Missing | 0.95  | 0.66  | - | 1.37  | 0.788  |
| Barthel Index | 100 | Reference |  |  |  |  |
|  | <100 | 1.68  | 1.28  | - | 2.22  | <0.001 |
|  | Missing | 1.17  | 0.61  | - | 2.26  | 0.636  |
| Radiotherapy |  | 2.15  | 1.69  | - | 2.73  | <0.001 |
| Central vein catheter |  | 1.66  | 1.05  | - | 2.60  | 0.029 |
| Thoracic drainage |  | 2.52  | 1.67  | - | 3.81  | <0.001 |
| Hypertension |  | 1.11  | 0.88  | - | 1.41  | 0.379  |
| Diabetes |  | 0.72  | 0.52  | - | 1.00  | 0.048  |
| Hyperlipidemia |  | 1.31  | 0.87  | - | 1.98  | 0.197  |
| Atrial fibrillation |  | 0.99  | 0.53  | - | 1.84  | 0.971  |
| Antithrombotic medication | 　 | 4.65  | 2.95  | - | 7.34  | <0.001 |

CBDCA, carboplatin; CDDP, cisplatin